 Myovant Sciences Ltd NYSE: MYOV opened nearly 35 up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a better offer Sumitovant Biopharma Ltd had sought to takeover the London-headquartered firm for 2.18 billion, as per the press release. 